JUNSHI BIO's Subsidiary Suzhou Zhonghe Passes FDA Inspection

Stock News

Oct 22

JUNSHI BIO (688180.SH) announced that its wholly-owned subsidiary, Suzhou Zhonghe Biopharmaceutical Technology Co., Ltd. (referred to as "Suzhou Zhonghe"), underwent a CGMP (Current Good Manufacturing Practice) inspection by the U.S. Food and Drug Administration (FDA) from June 16 to June 24, 2025. Recently, Suzhou Zhonghe received the Establishment Inspection Report (EIR) issued by the FDA, indicating that it has successfully passed this CGMP inspection. This marks the second successful FDA inspection for Suzhou Zhonghe, following its first success in 2023, highlighting the ongoing international recognition of the company's high-quality manufacturing system.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/1145977886"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"1145977886\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/1145977886?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-10-22 17:14","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1145977886","market":"us","top_or_hot":-1,"title":"JUNSHI BIO's Subsidiary Suzhou Zhonghe Passes FDA Inspection","media":"Stock News","content":"<p>JUNSHI BIO (688180.SH) announced that its wholly-owned subsidiary, Suzhou Zhonghe Biopharmaceutical Technology Co., Ltd. (referred to as \"Suzhou Zhonghe\"), underwent a CGMP (Current Good Manufacturing Practice) inspection by the U.S. Food and Drug Administration (FDA) from June 16 to June 24, 2025. Recently, Suzhou Zhonghe received the Establishment Inspection Report (EIR) issued by the FDA, indicating that it has successfully passed this CGMP inspection. This marks the second successful FDA inspection for Suzhou Zhonghe, following its first success in 2023, highlighting the ongoing international recognition of the company's high-quality manufacturing system.</p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>JUNSHI BIO's Subsidiary Suzhou Zhonghe Passes FDA Inspection</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nJUNSHI BIO's Subsidiary Suzhou Zhonghe Passes FDA Inspection\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1036600163\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock News </p>\n<p class=\"h-time\">2025-10-22 17:14</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>JUNSHI BIO (688180.SH) announced that its wholly-owned subsidiary, Suzhou Zhonghe Biopharmaceutical Technology Co., Ltd. (referred to as \"Suzhou Zhonghe\"), underwent a CGMP (Current Good Manufacturing Practice) inspection by the U.S. Food and Drug Administration (FDA) from June 16 to June 24, 2025. Recently, Suzhou Zhonghe received the Establishment Inspection Report (EIR) issued by the FDA, indicating that it has successfully passed this CGMP inspection. This marks the second successful FDA inspection for Suzhou Zhonghe, following its first success in 2023, highlighting the ongoing international recognition of the company's high-quality manufacturing system.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK0239","symbol_name":"医药制造","start_time":0,"source_url":"","article_id":"1145977886","we_media_id":"1036600163","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1145977886","pubTimestamp":1761124461,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Stock News","introduction":"Global Stock News First-Time Broadcast","home_visible":1,"id":"1036600163","head_image":"https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a"},"summary":"JUNSHI BIO (688180.SH) announced that its wholly-owned subsidiary, Suzhou Zhonghe Biopharmaceutical Technology Co., Ltd. (referred to as \"Suzhou Zhonghe\"), underwent a CGMP (Current Good...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"688180":"君实生物","BK0239":"医药制造","BK1583":"高瓴概念","01877":"君实生物","BK1515":"抗疫概念","BK1161":"生物科技"},"translate_title":"君实生物子公司苏州众和通过FDA检查","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"688180":1,"01877":1},"content_text":"JUNSHI BIO (688180.SH) announced that its wholly-owned subsidiary, Suzhou Zhonghe Biopharmaceutical Technology Co., Ltd. (referred to as \"Suzhou Zhonghe\"), underwent a CGMP (Current Good Manufacturing Practice) inspection by the U.S. Food and Drug Administration (FDA) from June 16 to June 24, 2025. Recently, Suzhou Zhonghe received the Establishment Inspection Report (EIR) issued by the FDA, indicating that it has successfully passed this CGMP inspection. This marks the second successful FDA inspection for Suzhou Zhonghe, following its first success in 2023, highlighting the ongoing international recognition of the company's high-quality manufacturing system.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"","news_rank":0,"symbols":[],"gpt_button":1,"need_auth":false,"code":"91000000","status":"200"}}}